TrumpRx Launch Brings Savings—and Uncertainty

With the tagline, “Delivering the lowest prescription prices in the world for Americans,” TrumpRx is set to launch this evening. Among the biopharmaceutical companies that have so far entered into most favored nation (MFN) pricing agreements with the Trump administration and will offer direct-to-consumer (DTC) sales through the online platform are Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Genentech, Gilead Sciences, GlaxoSmithKline, Merck & Co, Novartis, Novo Nordisk, Pfizer, and Sanofi.1

Some of the reported discounts that will be available include reducing monthly costs from $1000 and $1350, respectively, to $350 for Ozempic and Wegovy, both semaglutides and manufactured by Novo Nordisk; from $1086 to $346 for Zepbound (tirzepatide; Eli Lilly); and an initial price of $150 for FDA-approved oral glucagon-like peptide-1 (GLP-1) receptor agonists.2 At present, 25-mg oral semaglutide (Wegovy) is the only FDA-approved pill for weight loss; it is also approved to reduce the risk of major adverse cardiovascular events.3 Orforglipron was under investigation in the phase 3 ATTAIN-MAINTAIN (NCT06584916) trial, and Eli Lilly has submitted a new drug application to the FDA after topline results showed weight loss was maintained following a switch from an injectable weight-loss medication.4 If approved, the lowest dose of orforglipron would start at $149.5

First announced in September 2025, the launch of TrumpRx also follows an executive order issued in May 2025 that promised to reduce prescription drug prices by up to 59%6 and a pledge from GoodRx in January 2026 to match the Novo Nordisk price of oral semaglutide.7 No medications will be sold on the website; instead, patients are meant to use TrumpRx as a portal to access manufacturers’ websites and purchase the medications directly from them.8

First announced in September 2025, the online platform is set to offer access to prescription medications at steep discounts, with potential savings in the millions. | Image Credit: © TarikVision-stock.adobe.com

Insurance remains a sticking point, however, with the launch of TrumpRx, as purchasers are required to pay cash.1 As of today, health insurance will not be accepted; this conflicts with some manufacturer DTC programs that permit health insurance as payment.8 Experts also have cautioned that Americans could end up paying more if they go through the site; this is because most of the medications that will be available are already covered by insurance and have cheaper generic versions available.

Still, there are some that will be offered that are not typically covered by insurance, such as those used to treat infertility.8 For example, there are reports that follitropin alfa (Gonal-F; EMD Serono) could be offered at a 796% discount and that women with incomes below 550% of the federal poverty level would be eligible for an additional 2320% discount.9 As part of its agreement with the Trump administration, EMD Serono has also pledged to guarantee MFN prices on all new marketed medications and to manufacture in vitro fertilization medications in the US.

There are also concerns that previously announced threats from President Donald J. Trump, such as investigating pharmaceutical companies for anticompetitive practices and using the Federal Food, Drug, and Cosmetic Act to investigate drug safety, could have long-term implications for his successor.10 Health policy experts also have noted that savings will not be realized immediately or at all, and that all of the details from the deals the drug manufacturers pledge to fulfill may never be known, nor is whether these deals will remain in effect after Trump leaves office a second time.11 Much uncertainty, too, remains for the total impact on Medicaid programs, and some have thrown up alarms that there could be reduced investment in biotech innovation and development of new medicines, particularly by small and midsize firms.

References

1. Frolo C. Trump to officially launch TrumpRx, offering affordable prescription drugs to Americans. CNY Central. February 5, 2026. Accessed February 5, 2026. https://cnycentral.com/news/nation-world/trump-to-officially-launch-trumprx-bringing-affordable-prescription-drugs-to-americans-website-dr-oz-joe-gebbia-eli-lilly-pfizer-novo-nordisk-weight-loss-health-insurance-medicare-medicaid
2. Fact sheet: President Donald J. Trump announces major developments in bringing most-favored-nation pricing to American patients. The White House. November 6, 2025. Accessed February 5, 2026. https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/
3. Joszt L. FDA approved oral semaglutide as first GLP-1 pill for weight loss. AJMC®. December 23, 2025. Accessed February 5, 2026. https://www.ajmc.com/view/fda-approves-oral-semaglutide-as-first-glp-1-pill-for-weight-loss
4. Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial. News release. Eli Lilly. December 18, 2025. Accessed February 5, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after
5. Halpern L. Roundup: every Most Favored Nation agreement with the Trump administration. Pharmacy Times®. February 3, 2026. Accessed February 5, 2026. https://www.pharmacytimes.com/view/round-up-every-most-favored-nation-agreement-with-the-trump-administration
6. Bonavitacola J. Trump executive order could reduce pharmaceutical costs by 59%. AJMC. May 12, 2025. Accessed February 5, 2026. https://www.ajmc.com/view/trump-executive-order-could-reduce-pharmaceutical-costs-by-59-
7. Shaw ML. GoodRx to match Novo Nordisk price for oral semaglutide. AJMC. January 5, 2026. Accessed February 5, 2026. https://www.ajmc.com/view/goodrx-to-match-novo-nordisk-price-for-oral-semaglutide
8. Robbins R. TrumpRx is set to go live on Thursday. New York Times. February 5, 2026. Accessed February 5, 2026. https://www.nytimes.com/2026/02/05/us/politics/trumprx-website.html
9. Fact sheet: President Donald J. Trump announces actions to lower costs and expand access to in vitro fertilization (IVF) and high-quality fertility care. The White House. October 16, 2025. Accessed February 5, 2026. https://www.whitehouse.gov/fact-sheets/2025/10/fact-sheet-president-donald-j-trump-announces-actions-to-lower-costs-and-expand-access-to-in-vitro-fertilization-ivf-and-high-quality-fertility-care/
10. Nighohossiam J. The TrumpRx medicine will prove worse than the disease. Competitive Enterprise Institute. October 24, 2025. Accessed February 5, 2026. https://cei.org/blog/the-trumprx-medicine-will-prove-worse-than-the-disease/
11. Lim D. Trump’s drug-pricing deals won’t benefit most Americans today. They could over time. Politico. January 4, 2026. Accessed February 5, 2026. https://www.politico.com/news/2026/01/04/trumps-drug-pricing-deals-wont-benefit-most-americans-today-that-could-over-time-00706529